Non-Fucosylated Anti-Human Apolipoprotein C-III (C23-4) Therapeutic Antibody (CAT#: BioBet-575ZP) Datasheet

APOC3

apolipoprotein C-III

Apolipoprotein C-III is a very low density lipoprotein (VLDL) protein. APOC3 inhibits lipoprotein lipase and hepatic lipase; it is thought to delay catabolism of triglyceride-rich particles. The APOA1, APOC3 and APOA4 genes are closely linked in both rat and human genomes. The A-I and A-IV genes are transcribed from the same strand, while the A-1 and C-III genes are convergently transcribed. An increase in apoC-III levels induces the development of hypertriglyceridemia.

APOC3; apolipoprotein C-III; HALP2; APOCII

Extracellular region or secreted

Diseases associated with APOC3 include Apolipoprotein C-Iii Deficiency and Coronary Heart Disease 1.

Its related pathways are Lipoprotein metabolism and Signaling by GPCR.

Plasma is rich in triglyceride-rich very low density lipoprotein (VLDL) and high density lipoprotein (HDL) components. It plays a multi-faceted role in triglyceride homeostasis. In the cell, it promotes the assembly and secretion of very low density lipoprotein 1 (VLDL1) in the liver; outside the cell, it weakens the hydrolysis and clearance of triglyceride-rich lipoproteins (TRLs). By inhibiting the hepatic absorption of TRLs by lipoprotein lipase and residual receptors, the lipolysis of TRLs is impaired. It is composed of several curved spirals connected by semi-flexible hinges, so that it can be tightly wound on the curved micelle surface and easily adapt to the different diameters of its natural combination.

The most abundant glycoforms are characterized by an O-linked disaccharide galactose linked to N-acetylgalactosamine (Gal-GalNAc), further modified with up to 3 sialic acid residues. Less abundant glycoforms are characterized by more complex and fucosylated glycan moieties. O-glycosylated on Thr-94 with a core 1 or possibly core 8 glycan.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1

C23-4

Human

Human

The antibody are capable of binding to specific epitopes of Apolipoprotein C-III (ApoCIII), relates to novel therapies, and prophylactic treatments of dyslipidaemia, such as atherosclerotic diseases.

Atherosclerotic Diseases

Atherosclerotic Diseases